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The pentacyclic acridinium salt RHPS4 displays anti-tumour properties in vitro as well as in vivo and is
potentially cell-cycle speciﬁc. We have collected experimental data and formulated a compartmental
model using ordinary differential equations to investigate how the compound affects cells in each stage
of the cell cycle. In addition to a control case in which no drug was used, we treated colorectal cancer
cells with three different concentrations of the drug and ﬁtted simulations from our models to
experimental observations. We found that RHPS4 caused a concentration-dependent, marked cell death
in treated cells, which is best modelled by allowing the rate parameters corresponding to cell death to
be sigmoidal functions of time. We have shown that the model is ‘‘identiﬁable’’, meaning that, at least
in principle, the parameter values can be determined from observable quantities. We ﬁnd that at low
concentrations RHPS4 primarily affects the cells in the G2/M phase, and that the drug has a delayed
effect with the delay decreasing at larger doses. Since the drug diffuses into the nucleus, the observed
delayed effect of the compound is unexpected and is a novel ﬁnding of our research into this
compound.
& 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The study of anti-cancer agents has not yet generated an
efﬁcient remedy for most of the common cancer types, which
suggests that much research is still necessary to understand the
processes involved in cancer development as well as the mechan-
isms which speciﬁc anti-cancer treatments evoke. Tissue culture
experiments are frequently used to evaluate the ability of new
drugs to induce growth inhibition, changes in cell-cycle progres-
sion and cell death. Comparing the results from such experiments
to observations from in vitro experiments on cell components can
bring understanding into the actual mechanisms in living cells.
The eukaryotic cell cycle consists of ﬁve major phases, namely
a resting state G0 and four cycling phases G1, S (synthesis), G2 and
M (mitotic) phase with cells progressing in this order before
dividing into two cells back in phase G1. Growth factors activate
membrane receptors of a cell triggering cell-cycle entry, and
intracellular signal transduction pathways induce the activation
of cyclin-dependent kinases that control the transitions between
the cell-cycle phases (Aguda, 2001). Chromosome duplication,
during which DNA is replicated, occurs during the S phase. Due to
speciﬁc mechanisms of DNA synthesis, telomeres, the terminatingHirt).
BY-NC-ND license.DNA sequences at chromosome ends, shorten during cell division
(Levy et al., 1992). When telomeres reach a certain threshold length
called the Hayﬂick limit, cells enter a non-dividing state (senes-
cence), where cells remain viable until they normally undergo a
controlled form of cell death (apoptosis), which is often accompa-
nied by DNA degradation at later stages. The enzyme telomerase,
however, can antagonise telomere attrition by telomere elongation,
and this happens in about 90% of cancerous cells (Kim et al., 1994).
The compound RHPS4 (3,11-diﬂuoro-6,8,13-trimethyl-8H-
quino ½4;3,2kl acridinium methosulphate) is a potential anti-
cancer drug which has been found (Gavathiotis et al., 2003; Cheng
et al., 2008) to interfere with DNA replication processes that are
part of the cell cycle. Investigating the cell cycle dynamics can
give insight into whether we ﬁnd similar behaviour in living cells.
The drug RHPS4 stabilises guanine-rich structures at telomeric
ends inhibiting the binding of telomerase (Gowan et al., 2001).
The compound is an attractive agent because of its ability to
shorten telomeres by telomerase inhibition via exposure of cells
at low concentrations. Cookson et al. (2005a) showed a signiﬁcant
reduction in telomere length of MCF-7 breast cancer cells when
treated with subtoxic doses of RHPS4. Moreover, the drug can also
rapidly induce telomere dysfunction by altering telomeric chro-
matin leading to short-term cell death at higher doses (Salvati
et al., 2007). RHPS4 reduced the growth of human tumours
xenografted in mice in vivo and did not show any toxic effect in
mice. Additionally, treatment with RHPS4 of human melanoma
Fig. 1. A cell cycle model of viable cells including death from each of the three
phases.
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dependent decrease in cell replication and accumulation of cells
in the S-G2/M phase of the cell cycle after 6 days (Leonetti et al.,
2004).
Mathematical modelling can be a useful means for integrating
different types of experimental data in medical applications to
predict the mechanism of action of compounds to be investigated
(Wolkenhauer et al., 2009). Modern experimental techniques
generate a vast amount of data that have to be interpreted and
systematic information be extracted, which is often beyond the
scope of traditional techniques. For instance, the development of
mathematical models is essential to deal with the complexity of
cell cycle processes and cell cycle regulation (Fuss et al., 2005),
which are an important part of cancer development studies in
biotechnology and medicine.
A variety of mathematical models of the cell cycle can be found
in the literature. A quantitative description of cell cycle dynamics
based on the time cells spend in each phase of the cell cycle is
presented by Montalenti et al. (1998). Panetta and Adam (1995)
developed a two-compartment ordinary differential equation (ODE)
model of cycling and resting cells. Sherer et al. (2008) used a partial
differential equation (PDE) model consisting of three compartments
which represent the G0þG1 phase, the S phase and the G2þM
phase. DNA histograms of the total cell population provide data for
this model, which can be used to estimate corresponding transition
rate functions. More detailed models, distinguishing further
between single phases of the cell cycle, use mixtures of ODEs and
PDEs, as proposed by Basse et al. (2005), Basse and Ubezio (2007)
and Venkatasubramanian et al. (2008). In addition, several models of
cell cycle regulation describing molecular interactions in different
pathways of the cell cycle control apparatus are given by Tyson
(1991), Tyson and Novak (2001) and Yang et al. (2006). Further
references regarding cell cycle models of tumour development and
spatio-temporal response to cell-cycle speciﬁc anti-cancer agents
can be found in Johnson et al. (2011).
We use a systems biology approach to investigate how the drug
RHPS4 changes the cell cycle dynamics over short periods of time
and at medium drug concentrations (50–1000 nM). We formulate a
novel cell-cycle model distinguishing between viable and dead cells
of the same DNA content and report results of the best ﬁt of model
to experimental data. Our method involves new experimental
design, the application of effective parameter estimation, and
statistical model evaluation techniques to gain a more detailed
insight into the actual dynamics of cells in drug assays and more
information on the accuracy of the results obtained.
To keep the model structure simple we develop an ODE model
based on the experimental data, where we assume that the phase
of resting cells is negligible, as cells from the HCT116 cell line in
our experiments have a relatively high doubling rate. We also
simplify our model by including senescent cells into the compart-
ment of G0/G1 cells, as the proportion of senescent cells in an
RHPS4 assay does not substantially change over the time-scale of
10 days (Johnson et al., 2011), which we use in our assays. Our
model allows for cell death from all cell-cycle phases and we
distinguish between early and late stages of cell death, the latter
of which being characterised by DNA fragmentation processes.
In Section 2 we present the mathematical model of cell-cycle
dynamics and introduce a statistical model which we use to describe
the experimental data. Numerical methods involved in the estima-
tion of cell cycle parameters and statistical techniques for model
inference and comparison are given in Section 3 followed by a
summary of the experimental results and the results from model
ﬁtting in Section 4. Information given in Section 4 includes an
analysis of the accuracy of model-data ﬁt and an investigation of the
biological implications of our results. Discussion of the presented
work and conclusions are drawn in Section 5.2. Mathematical model formulation
2.1. Model of cell cycle dynamics
The aim of our model is to ﬁnd how the drug RHPS4 affects
cells of the HCT116 line through their cell cycle and growth. In
order to compare simulations from mathematical models to real
dynamics, we have used a ﬂow cytometer to measure the DNA
content of cells and derived cell cycle distributions by evaluating
the corresponding DNA histograms. Viable cells were distin-
guished from dead cells by trypan blue dye exclusion, and the
total number of cells in each cell population was determined daily
for 10 days. Our model is constructed according to experimental
data collected in the tissue culture laboratory (see Appendix A for
the experimental techniques).
The proportions of viable and dead cells and proportions of
cells in the phases, G0/G1, S, G2/M, of the cell cycle have been
collected under control conditions and under treatment with
different concentrations (50 nM, 100 nM and 1 mM) of the poten-
tial anticancer drug RHPS4 over 10 days. The phases G0/G1, S,
G2/M have been distinguished by their DNA content in a cell,
being onefold during the phases G0 and G1, twofold during phases
G2 and M, and between one- and twofold during the synthesis
phase S. Cells identiﬁed to be in one of these cell cycle phases are
either viable or have been measured a short time after the onset
of cell death. Pre-G1 cells are dead cells being detected some time
after the onset of cell death and contain fragmented DNA with
less DNA content than a G0/G1 cell. A cell cycle model of viable
cells is depicted in Fig. 1. Cell death is indicated by loss of cell
material from each of the three cell-cycle phases.
The cell states that can be detected suggests the assignment of
seven compartments, namely X, Y, Z for viable cells being in G0/G1,
S, G2/M, respectively, X , Y , Z for cells dying recently in each of the
cell-cycle phases, and A for all pre-G1 cells. However, experi-
mental measurements do not allow us to distinguish between
viable and dead cells of the same DNA content. The observable
states therefore differ from the classiﬁcation, we can only observe
cells in XþX , YþY , ZþZ , XþYþZ, XþY þZþA and A.
Viable cells go around the cell cycle X-Y-Z-2X- . . ., where
cells double in number at the transfer from Z to X. It is possible
that cells die from each of the phases G0/G1, S, G2/M of the cell
cycle, that is, X-X , Y-Y and Z-Z . Once cells have died, their
DNA cannot be synthesised anymore and their nucleus is subject
to DNA degradation, hence X-A, Y-A, Z-A. Fig. 2 illustrates the
7-compartment model including the observable states.
We use the principle of mass action to model the dynamics
with the following system of ODEs
dX
dt
¼ 2kZXZðkXYþkXX ÞX, ð1Þ
dY
dt
¼ kXYXðkYZþkYY ÞY , ð2Þ
dZ
dt
¼ kYZYðkZXþkZZ ÞZ, ð3Þ
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dt
¼ kXX XkXAX , ð4Þ
dY
dt
¼ kYY YkYAY , ð5Þ
dZ
dt
¼ k
ZZ
ZkZAZ , ð6Þ
dA
dt
¼ kXAXþkYAY þkZAZ , ð7Þ
with initial values ðX,Y ,Z,X ,Y ,Z ,AÞT9t ¼ 0 ¼ ðX0,Y0,Z0,X0,Y 0,Z0,
A0ÞTZ0 being non-negative. Transition rates between compart-
ments are denoted by k subscripted with labels corresponding to
relevant compartments (e.g. kXY is the rate of transition from the X
to the Y compartment) and are assumed to be non-negative and
constant. The nature of the experimental data presented later (in
Section 4) suggests that we allow the rate coefﬁcients governing
transition from viable cells to dead cells to be time-dependent,
that is we let kn ¼ knðtÞ where ðnÞ represents XX , YY , or ZZ .
We have used several models for the transition rate functions
knðtÞ to ﬁt the 7-compartment model to experimental data, a
choice of which is given in Fig. 3. The basic rate functions describe
(M0) constant behaviour: knðtÞ ¼ kn0,
(M1) a sigmoidal increase: knðtÞ ¼ kn0þDknDkn=ð1þðt=t0ÞbÞ,
the change occurring around the time point t0, where the
magnitude of the increase in rate knðtÞ is Dkn and b is a shape
parameter. Note that the rate function model M0 is the special
case of M1 with Dkn¼0. The choice of each of the parameters inFig. 3. A schematic illustration of (i) rate model M0 and rate model M1 with (ii) sm
7-compartment model in Fig. 2. kn0 denotes the initial rate of cell death, t0 the time poin
n is a shape parameter of model M1.
Fig. 2. A 7-compartment model with compartments X, Y, Z, X , Y Z , A, arising from
the nature of the collected data in Appendix A. Transition rates kn between
compartments are assumed to be constant except for kX, kY, kZ possibly being
time-dependent functions. We group together the observed quantities, that is the
number of cells in each phase G0/G1, S, G2/M, pre-G1 (oval), and viable, dead cells
(rectangular areas).the transition functions will later be evaluated and the best model
chosen to ﬁnd the most appropriate description of the cell cycle
dynamics for each drug concentration.
2.2. Statistical model of experimental data
It is helpful to write the model (1)–(7) in vector form: The
cell-cycle dynamics are modelled by a system of ODEs of the form
dvðt,pÞ
dt
¼ Aðt,hÞvðt,pÞ, 0rtrte, ð8Þ
vð0,pÞ ¼ v0, ð9Þ
where v is the m-dimensional vector of state variables and t
denotes the time in the interval ½0,te. The parameter vector
p¼ ðh,v0Þ with domain HDRL is an L-dimensional vector of l
unknown rate parameters hk, k¼ 1, . . . ,l, and m initial conditions
ðv0Þj, j¼ 1, . . . ,m, ðL¼ lþmÞ and A is an mm matrix with entries
that depend on h and possibly t. For example, for rate model M1,
we have te¼10, m¼7, l¼13, L¼20, v¼ ðX,Y ,Z,X ,Y ,Z ,AÞT and
h¼ ðkXY ,kYZ ,kZX ,kXX0,DkXX ,kYY0,DkYY ,kZZ0,DkZZ ,t0,kXA,kYA,kZAÞ:
ð10Þ
Whilst our model has m¼7 quantities ðX,Y ,Z,X ,Y ,Z ,AÞ, only
M¼5 independent quantities are measured, respectively w1 ¼
XþX , w2 ¼ YþY , w3 ¼ ZþZ , w4 ¼ XþYþZ and w5 ¼ A. Hence the
vector w of measurements obtained is a linear combination of v,
this is, w¼ Bv, where
B¼
1 0 0 1 0 0 0
0 1 0 0 1 0 0
0 0 1 0 0 1 0
1 1 1 0 0 0 0
0 0 0 0 0 0 1
0
BBBBBB@
1
CCCCCCA: ð11Þ
Before estimating parameters it is useful ﬁrst to check whether
the model (1)–(7) is identiﬁable (see Walter and Pronzato, 1996
for a review of identiﬁability analysis). An identiﬁable model is
one for which the unknown parameters of the model, our rates kn,
can be uniquely recovered from the observed data under ideal
conditions, that is, assuming we have error-free and continuous
data for all observables available. We have conﬁrmed using the
transfer function method (Cobelli and Distefano, 1980; Jacquez,
1996) that our model is identiﬁable.
In our model the observables wj are observed with noise.
Hence we model wj as a random variableWj. Our statistical model
for WjðtiÞ, j¼ 1, . . . ,M, i¼ 1, . . . ,n, the jth observable at ith time
point, is
lnWjðtiÞ ¼ lnðB vðti,pÞÞjþeij, ð12Þ
where eij are the measurement errors, which we assume are
independently and identically distributed as eij Nð0,s2Þ with
variance s2. This choice of error distribution seems appropriateall b and (iii) large b, governing transition from viable cells to dead cells in the
t of the onset of signiﬁcant cell death, Dkn the magnitude of the increase in rate and
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replication process, in which Gaussian variation in the growth
rates will generate a log-normal error structure in the obtained
cell numbers (Koch, 1966; Limpert et al., 2001).3. Numerical methods/analysis
3.1. Parameter estimation
The parameters to be estimated in our model (12) are a
maximum of l¼13 rate parameters hk and m¼7 initial conditions
ðv0Þj whose values are not known exactly. We use a least squares
approach for determining optimal parameter values. The approach
is equivalent to maximising the likelihood function under model
(12), that is, maximising the probability that, for a given parameter
vector a¼ ðp,sÞ, certain realisations wiðtiÞ of the random variables
WjðtiÞ occur, interpreted as a function of a. The sum of the squared
residuals is
f ðpÞ ¼
Xn
i ¼ 1
XM
j ¼ 1
e2i,jðpÞ, ð13Þ
where
ei,jðpÞ ¼ lnðBvðti,pÞÞjln wjðtiÞ: ð14Þ
The least-squares parameter estimate is
p^ ¼ arg min
pAH
f ðpÞ, ð15Þ
which we compute using a Stochastic Ranking Evolutionary Strategy
(SRES) (Runarsson and Yao, 2000) followed by local optimisation
using the Levenberg–Marquardt (LM) method. SRES uses the idea of
treating parameter sets as the ‘genome’ of an individual and a
procedure of selection, recombination and mutation is repeated over
G generations to ﬁnd an optimal parameter set. We performed
calculations in MATLAB using an ODE solver (ode45) for the
numerical integration of (1)–(7), using the implementation from
Kleinstein et al. (2006) with G¼500 for the SRES algorithm, and
using the function lsqnonlin for the LM optimisation.
3.2. Practical identiﬁability: accuracy of parameter estimates
Besides calculating p^, we can also characterise the accuracy of
this estimate. By an asymptotic result (Seber and Wild, 1989), the
approximate sampling distribution of p^ under the model assum-
ing the true parameter value pn, is
p^ N Lðpn,R^Þ, ð16Þ
where N Lð,Þ denotes the L-dimensional multivariate normal
distribution and R^ ¼ Covðp^Þ denotes the covariance matrix of
the least-squares parameter estimate. The covariance matrix of p^
indicates whether parameters are practically identiﬁable, that is,
whether we can accurately infer values for the parameters. If
we assume that the model residuals ei,jðpÞ are approximately
linear in a small neighbourhood of p^, we can derive the covar-
iance matrix of p^ from linear regression analysis (Ashyraliyev
et al., 2008), that is
R^ ¼ s^2ðJFðp^ÞT JFðp^ÞÞ1, ð17Þ
where F is a vector function in p obtained by stacking the
columns en,j, j¼ 1, . . . ,M, of the matrix ðei,jÞ into a vector, and
JFðpÞ ¼
@FiðpÞ
@pk
 
, ð18Þ
is the Jacobian of F of size N L. The quantity s^2 ¼ f ðp^Þ=ðNLÞ is
an unbiased estimator of s2, where N¼M  n is the number ofexperimental measurements. The diagonal elements of R^ are the
marginal variances of the parameter estimates p^k, k¼ 1, . . . ,L.
3.3. Model selection
Having found best ﬁts for both models M0 and M1 to experi-
mental data, the most appropriate model for each of the given drug
concentrations has to be selected. A danger in choosing a model
which is meant to describe the observations from certain experi-
ments, is overﬁtting the experimental data by introducing many
parameters. We prefer to choose the model with the smallest
number of parameters, which still describes the underlying dynamics
sufﬁciently well. The Akaike information criterion (Akaike, 1974)
(AIC) is an information-theoretic criterion for model comparison,
which incorporates not only the objective function value f ðp^Þ but
also a penalty based on the number of parameters in the model,
hence it characterises the trade-off between goodness of ﬁt and
model complexity. When comparing two models according to the
Akaike criterion, they must be ‘nested’ in the sense that the
parameter space of one model is a lower dimensional subspace of
the other model. The value of the Akaike criterion is given by
mAIC ¼N lnðf ðp^ÞÞþ2ðLþ1Þ, ð19Þ
where N is the number of experimental measurements, f is the sum
of the squared residuals and L is the number of parameters which
have been ﬁtted to the data (L is the sum of the number of rate
parameters (l) and the number of initial conditions (m)) in each
model. The correction term
mcAIC ¼ mAICþ
2ðLþ1ÞðLþ2Þ
NL2 , ð20Þ
(Bedrick and Tsai, 1994) should be used for smaller sample sizes,
Nr40ðLþ1Þ. The candidate model with the smallest value mAIC is the
selected model.4. Results
4.1. Experimental results
We have measured cell cycle distribution and cell growth
experimentally and have produced normalised data sets as
described in Appendix A. Day 1 is the ﬁrst day of analysis when
measurements have been taken. We observe that control cells
grow exponentially between day 1 and day 9 as represented by
the approximately linear increase for log NðtiÞ, i¼ 1, . . . ,10, the
logarithm of the total cell number, plotted in Fig. 4. The data point
of control cells at t10 is markedly lower than the data point at t9,
which is due to conﬂuence and probably nutrient deﬁciency in
the wells; we therefore disregard this data point in our analysis.
Error bars result from the standard deviation over six replicates
and are rather small (around 10%). It is important to note that
they do not account for variability within different cell batches or
repeated experiments incorporating intermediate breaks, as the
replicates were obtained from cells of the same batch being
seeded in six parallel wells. Further comments on the particular
cell behaviour can be found in the discussion section.
For treated cells, we observe growth inhibition, and in general
cell growth declines with increasing drug concentration. The total
number of doublings at day 4 is 3.78 for control cells, 3.18 for
50 nM, 2.15 for 100 nM and 1.56 for 1 mM. A considerable growth
reduction occurs after a period of 6–7 days for 50 nM, 3–5 days
for 100 nM and 3–4 days for 1 mM of RHPS4, and respective total
cell numbers begin to level off thereafter.
The average proportion of dead cells was around 14% for
control cells, and low proportions of pre-G1 cells (cells with
Fig. 5. Distributions of the DNA content for control cells analysed at day 4 (left) and day 10 (right) with manually set gates for the estimation of the corresponding cell
cycle distributions.
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Fig. 4. Total numbers NðtiÞ of cells and the numbers of dead cells (measured by trypan blue dye-exclusion, lower proportion of each bar) for no drug and each drug
concentration (50 nM, 100 nM, 1 mM) of RHPS4 are shown on a log scale at day ti, i¼ 1, . . . ,10 of analysis. Error bars represent the standard deviations of the corresponding
values.
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ment, the proportion of S phase and G2/M phase cells ranged from
4% to 28% and from 8% to 30%, respectively, over the period of
observation. These proportions tended to decrease gradually from
higher to lower levels. Accordingly, the proportions of G0/G1 cells
increased from 50% to 80%, that is, control cells progressively
accumulated in the G0/G1 phase.
Interestingly, the proportion of treated cells in the S phase
tended to drop from around 25% at the beginning of the experiment
to about 8.5% on average by day 4 and returned to a slightly higher
level of around 15% after this drop. The most dramatic effect was
achieved with 1 mM of drug when the S phase proportions dropped
to about 5% at day 4. The proportions of G2/M cells behaved in a
similar way but with less remarkable trends, 30% at day 1 decreasingto 20% at day 4 and 18% on average during the subsequent days. The
proportion of cells in the G0/G1 phase increased during the ﬁrst
4 days from an average of 45%–65% and thereafter decreased to
around 50% for all treated cells. Before the onset of considerable
cell death, the proportions of pre-G1 cells remained at a low level
of about 1–4% for all drug concentrations, and then increased to
around 25%, where the increase occurred at a later time point, day 9,
for the highest drug concentration. Strikingly, in the experiments
with 50 nM and 100 nM of RHPS4, the proportions of pre-G1 cells
were observed to go down again after day 7, to around 3–14%,
which is possibly due to disintegration of dead cells in media.
Typical DNA distributions were obtained from the ﬂow cytometer at
days 4 and 10 and are shown for control cells in Fig. 5 and for cells
treated with 1 mM RHPS4 in Fig. 6.
Fig. 6. Distributions of the DNA content for cells treated with 1 mM of RHPS4 analysed at day 4 (left) and day 10 (right) with manually set gates for the estimation of the
corresponding cell cycle distributions.
Fig. 7. The objective function values f ðpÞ are plotted against generation number G for several repeats of the optimisation routine with a logarithmic scale for the ordinate.
The results of ﬁtting model M1 to data from HCT116 cells treated with 50 nM and 100 nM of RHPS4 are shown. The algorithm converges especially rapidly during the ﬁrst
100 generations, and 30 repeats have been run over 500 generations to identify the global minimum.
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7 for 50 nM, at day 5 for 100 nM and at day 4 for 1 mM of RHPS4,
when nearly all cells died abruptly from a prior level of around
15% at the beginning of the experiment. The intensive cell death
set in more abruptly for lower drug concentrations than for
higher doses. Altogether, the drug RHPS4 seems not only to affect
entry into the cell cycle (S/G2/M phases) around day 4, but also to
inhibit cell growth up to a complete cessation of the replication
processes with increasing drug concentration.
4.2. Results of best ﬁt of mathematical model
We ﬁtted the submodels M0 and M1 (see Fig. 3) to the
experimental data from each of the different treatments with
RHPS4 to investigate the cell cycle dynamics described by the
transition rates k of cells moving between cell-cycle phases.
Estimating the initial conditions directly from experimental data
did not notably inﬂuence the best ﬁt and resulted in a higher
accuracy for the estimated rate parameters (more than 75%
reduction in standard errors). We chose estimates of initial valuesv0 according to experimental data at day 1 assuming that cells do
not replicate during the ﬁrst day of incubation and that the
proportions of viable cells in each of the cell-cycle phases G0/G1, S,
G2/M do not differ from the proportion of viable cells across the
total cell population at day 1.
We used the global optimisation method to ﬁnd that the
parameter estimate p^ converged rapidly to close proximity of
the global minimum during the ﬁrst G¼100 generations (see
Fig. 7), and in every case of the 30 repeated runs of the SRES
algorithm, based each time on a different random initial guess for
p^, the ﬁnal cost function values were found to be close to the
minimal cost. The parameter values obtained from the repeated
runs of the SRESþLM routine showed (see Supplementary Material
for an illustration of the case of 50 nM RHPS4) that the convergence
of the method is relatively stable and a unique minimum could be
identiﬁed.
We calculated mcAIC to select between M0 and M1, for each drug
concentration. Table 1 shows the values of mcAIC, as well as the
values of the cost function f and the variance estimates s^2,
suggesting that model M0 describes best the behaviour of control
B.V. Hirt et al. / Journal of Theoretical Biology 295 (2012) 9–22 15cells and model M1 the dynamical behaviour of treated cells.
A value of b¼10 was used for model M1 (sigmoidal rate increase)
as smaller values of b resulted in worse ﬁts. In particular, values
of br3 did not ﬁt the data showing that the drug introduces not
gradual but abrupt changes in the number of viable cells. Note
that, for control cells, the model with a higher cost function
value but a smaller number of parameters has been chosen. For
increasing drug concentration, the data variance estimator
increases from about 0.2 (control) to 0.5 (1 mM RHPS4) indicating
that more variability occurs in the data at higher doses of RHPS4.
We found very low parameter values for kYY0 and kZZ0 in
control cells, which causes parameter identiﬁability problems for
kYA and kZA, as the choice of those parameter values, with Y , Z
being practically zero, did not inﬂuence the model dynamics
signiﬁcantly. Therefore, we reﬁtted model M0 with only ﬁve
parameters, setting kYY0 ¼ kZZ0 ¼ kYA ¼ kZA ¼ 0. The choice of the
reduced model, denoted by Mn0, resulted in similar parameter ﬁts
(see Table 2), but a smaller value of mcAIC (Table 1) compared to
model M0, conﬁrming the model reduction.Table 1
The optimal objective function values fmin ¼ f ðp^Þ and variance estimates s^2 for the
model residuals are given for models M0 and M1 and each concentration of the
drug RHPS4, and the model ﬁts are compared with respect to their values mcAIC of
the corrected Akaike criterion. Data of model Mn0 is given for 0 nM, of model M
n
1 for
100 nM and 1 mM, and of model Mnn1 for 50 nM RHPS4 only. The ‘best’ model is
chosen according to the lowest value of mcAIC.
RHPS4 Model
type
fmin s^2 mcAIC Model
chosen
0 nM M0 8.1856 0.189 138.64
M1 7.9739 0.194 150.88
Mn0 8.2152 0.168 127.51 |
50 nM M0 118.29 2.319 310.88
M1 17.481 0.372 209.00
Mnn1 17.481 0.343 196.16 |
100 nM M0 50.604 0.992 259.93
M1 20.985 0.446 219.96
Mn1 20.985 0.411 207.12 |
1 mM M0 36.423 0.714 240.20
M1 26.038 0.554 232.91
Mn1 26.038 0.511 220.06 |
Table 2
Results of parameter estimation. The transition rates k are displayed in
with respective residence times TX, TY, TZ of cells in the G0/G1, S, G2/M ph
cell death) given in units of hours. Cells die with rates kn0þDkn after th
chosen in Table 1. Parameter values for model M0 and model M
n
0 are g
RHPS4 (0 nM) 0 nM
Model M0 Mn0
TX 10.6 10.6
TY 3.21 3.22
TZ 5.02 5.01
Td 19.8 19.8
kXY 2.03 2.03
kYZ 7.47 7.45
kZX 4.78 4.79
t0 – –
k
XX0 2:36 101 2:35 101
k
YY 0 4:87 1017 –
k
ZZ0 3:28 1016 –
k
XX0þDkXX 2:36 101 2:35 101
k
YY 0þDkYY – –
k
ZZ0þDkZZ – –
kXA 1:63 101 1:70 101
kYA 1:20 1014 –
kZA 4:54 101 –Similarly, we reduced model M1 by setting kYY0 ¼ kZZ0 ¼ kYA ¼
kZA ¼ 0 for cells treated with higher drug concentrations (model
Mn1) and setting kXX0 ¼ kYY0 ¼ kXA ¼ kYA ¼ 0 for treatment with
50 nM RHPS4 (model Mnn1 ). This has been suggested by all of
those parameters kn0 satisfying ko106/day, with parameters kn0
that have not been removed taking values larger than 101/day.
Furthermore, lower mcAIC values for model M
n
1 and model M
nn
1 than
for model M1 supported our choice of model reduction.
There is good agreement between model predictions of the
selected models and experimental data, especially for control and
50 nM of RHPS4. The simulated and observed data are shown for
each concentration and each observed quantity in Fig. 8. For higher
drug concentrations, the simulations overestimate the number of S
phase cells at day 4. However, there is more noise in the data with
increasing concentration of RHPS4, and the model still captures the
major trend of the cell cycle dynamics well.4.3. Parameter ﬁtting—model results
The simulations of the dynamical behaviour of viable cells
conﬁrm that control cells grow exponentially, with the number of
G0/G1 cells being larger than the number of G2/M cells and the
G2/M cell numbers being slightly larger than the number of
S-phase cells across the observation period. The doubling time
Td¼19.8 h simulated for control cells is within biological varia-
bility of the value Td¼20.5 h quoted by Brattain et al. (1981). Cells
die from the G0/G1 phase, the number of non-viable S-phase and
G2/M-phase cells remain at a constant, very low level (see left panel
of Fig. 9). Note that t has been shifted one unit to the left in the
diagrams in accordance with the ﬁrst measurements being on day
1 of the experiments, so this is when we assume cell growth to start.
When the drug is added to the cells, the cell cycle dynamics
change markedly. The numbers of viable cells in each phase of the
cell cycle decay exponentially after an initially exponential
increase and nearly vanish at the end of the observation period
(see right panel of Fig. 9 for 50 nM and Fig. 10 for 100 nM and
1 mM RHPS4). Whereas the rate xs of the exponential increase
does not differ much across treatments (xsA ½0:6=day,0:8=day,
setting knðtÞ ¼ kn0 in Appendix B), exponential decrease occurs
with rates (xs ¼2:2458=day for 50 nM, xs ¼0:98828=day forunits of 1/day for all concentrations of the drug RHPS4, together
ase and doubling times Td of viable cells (before the time of marked
e time point t0. The presented values stem from the ‘best’ models
iven for comparison.
50 nM 100 nM 1 mM
Mnn1 M
n
1 M
n
1
13.2 7.18 12.4
3.16 4.07 4.70
2.08 7.37 8.23
20.8 20.1 27.3
1.82 2.98 1.72
7.59 5.90 5.10
9.84 3.26 2.92
5.12 2.46 1.68
– 3:61 101 2:11 101
– – –
1.72 – –
3.21 3.13 1.86
2.90 1.58 8:88 101
5.98 1.44 1.36
– 7:05 102 2:56 102
– – –
1:71 101 – –
Fig. 8. Solutions of the model ﬁtting procedure to experimental data. Simulations stem from the ‘best’ models chosen in Table 1. Model curves are represented by lines and
experimental data by different markers dependent on the states observed and logarithmic scales have been taken on the vertical axes. ‘A’ denotes pre-G1 cells and is a
subset of nonviable cells. Standard deviations of the experimental data are not shown for better visibility of the markers and would be largely smaller than the symbols.
B.V. Hirt et al. / Journal of Theoretical Biology 295 (2012) 9–2216100 nM, xs ¼0:68232=day for 1 mM RHPS4, setting knðtÞ ¼ kn0þ
Dkn in Appendix B) which decline markedly with increasing drug
concentration. Model analysis revealed that we ﬁnd oscillations
for values of t close to 0, which vanish rapidly as t increases. Thepeak of the number of viable cells is shifted towards earlier times
at increasing drug concentration. The number of pre-G1 cells
grows exponentially for control cells and in the second half of the
observation period, linearly for treated cells due to the number of
Fig. 9. Cell cycle dynamics simulated for the behaviour of control cells (left: log-plot for better visual distinction between the different phases of the cell cycle) and for the
behaviour of cells treated with 50 nM of RHPS4 (right: normal scale on vertical axis). The asterisk in front of phase names in the legend denotes dead cells.
Fig. 10. Cell cycle dynamics simulated for the behaviour of cells treated with 100 nM ð1 mMÞ of RHPS4 are shown on the left (right) side of this ﬁgure. Simulations stem
from model ﬁtting to experimental data. The asterisk in front of phase names in the legend denotes dead cells.
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tion of 50 nM, however, the model predicts a higher number of
viable S-phase cells than viable G2/M-phase cells across the
observation period contrary to respective trends for control cells,
100 nM and 1 mM treatments.
Table 2 displays all estimated rate parameter values and some
derivations such as doubling times for each concentration of
RHPS4. Control cells spend about 10.6 h in the G0/G1 phase,
3.2 h in the S phase and 5.0 h in the G2/M phase according to
the ﬁtted parameters. The rates of transition between compart-
ments of viable cells and the average amounts of time TX, TY, TZ
(see Appendix B for deﬁnition) a cell spends in each of the cell
cycle phases X, Y, Z, do not display a trend with respect to changes
in drug concentration. Notable changes predicted by the models,
however, are in TZ for 50 nM, being less than half the length of the
corresponding estimates for control cells, and in TZ for 100 nMand 1 mM, being about 1.5 times this length. The time point t0
around which the transition rates to cell death increase by Dkn, with
knðt0Þ ¼ kn0þDkn=2, decreases from 5.12 days to 1.68 days with
increasing drug concentration, where the decrease is more signiﬁ-
cant for the lower drug concentrations than for 1 mM RHPS4.
There is no visible trend predicted by the model for cells dying
before the time point t0. Control cells and cells treated with higher
drug concentrations die with lower rates ðkXX0o0:4=dayÞ from the
G0/G1 phase, cells treated with 50 nM die markedly ðkZZ0 ¼ 1:72=dayÞ
from the G2/M phase. There is practically no death from the S phase
before t0. After the time point t0, treated cells die with signiﬁcantly
higher rates from all phases of the cell cycle. In particular, cells
treated with 50 nM RHPS4 undergo cell death from G2/M with a
markedly higher rate ðkZZ0þDkZZ ¼ 5:98=dayÞ than from the other
cell cycle phases. DNA degradation in cells occurs largely from each of
the phases of the cell cycle in which cells die before the time point t0.
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We evaluate how accurate our chosen model reﬂects the
properties of the collected data by employing statistical signiﬁ-
cance tests. In writing down model (12), we have made several
assumptions, namely that the model describes the underlying
dynamics sufﬁciently accurately, and that errors are independent
and log-normally distributed with the same standard deviation s.
Under the model the residuals ei,j are independent with a Nð0,s2Þ
distribution. Using the Anderson–Darling Statistic (Stephens,
1974, 1976) we found no evidence at a 5% signiﬁcance level
against the hypothesis that ei,j Nð0,s2Þ. Furthermore, using a
t-statistic (Kraemer, 1975) we found no evidence against the
assumption that residuals are independent. We also have not
found any signiﬁcant autocorrelation (Cedersund and Roll, 2009),
that is eiþ1,j being correlated with ei,j, i¼ 1, . . . ,n1, over the time
points of observation in the residuals. Most of the p-values were
larger than 0.5, none of them being smaller than 0.15. The level of
correlation in residuals for control and at 50 nM RHPS4 is very low
(p40:1 for most pairs of residuals), indicating that our models
capture the dynamics well. Fig. 11 displays the residuals ei,j for the
case of 50 nM of RHPS4. For higher drug concentrations, we ﬁnd
statistically signiﬁcant ðpo0:05Þ correlation between residuals from
XþX , YþY , ZþZ , XþY þZþA, indicating that there is some
systematic variability in the data that the model does not capture.
The near-linear relationships between residuals may be caused by
secondary dynamics in nonviable cells, which are not accounted for
in our model.
An illustration of the estimates of the rate parameters for the
four RHPS4 assays with respective standard errors is given in
Fig. 12. Standard errors correspond to local analysis around p^ and,
therefore, large error bars indicate low accuracy in a neighbour-
hood around the optimal parameter. Consequently, error bars do
not indicate the full range of possible parameter values for the
model to be a good prediction of the cell cycle dynamics.Fig. 11. Residuals ei,j for time points ti, i¼ 1, . . . ,10, and model categories j¼ 1, . . . ,6, a
with 50 nM of RHPS4, respectively. There is no evidence at a 5% level (Anderson–Darling
distribution. ‘A cells’ in the legend denotes pre-G1 cells.
Fig. 12. Parameter estimates for control cells and treatment of cells with 50 nM, 100 n
(treated cells). Standard errors of parameter estimates result from model ﬁt to experimThe degree of correlation in the model parameters was evaluated
by computing the correlation matrix of p^ (see Appendix C) for each
drug concentration. For the control case and higher drug concentra-
tions, we found only weak correlation between parameters. There is,
however, a positive correlation between kZX and kZZ0 for treated
cells with 50 nM RHPS4, meaning that, with parameter values being
at the current level, certain proportional changes in kZX and kZZ0 do
not signiﬁcantly inﬂuence the model predictions in a close neigh-
bourhood of the estimated parameter values. Hence, good predic-
tions for these parameters lie within a narrow ellipsoidal region in
the kZX–kZZ0-plane, whose orientation and length of principal axes
can be estimated (Draper and Smith, 1998). Thus, the parameter
values can be slightly lower or higher but must approximately
satisfy kZX  5 kZZ0. Lower accuracy and strong correlation between
kZX and kZZ0 suggest that the drug effects on these parameters may
be less dramatic at 50 nM RHPS4 than originally inferred from
model ﬁtting.4.5. Biological implications
We ﬁnd that the drug affects the cell cycle phases differently at
lower and higher concentrations. High concentrations do not have
a cell-cycle speciﬁc effect on cells over the total observation
period, whereas low concentrations seem to affect the G2/M
phase by increasing the rate of transition to the G0/G1 phase
indicating fewer or faster processes occurring in the G2/M phase,
which simultaneously introduce marked cell death from G2/M
over the period of observation.
Furthermore, we observe a drug-dependent behaviour in
terms of cells undergoing cell death around t0 (the time point of
signiﬁcant cell death), where higher drug doses reduce the delay
to the onset of marked cell death, which occurs in a largely
cell-cycle independent manner. The delay in the effects of the
drug can be interpreted either as the time which the drug requiresre plotted on the time scale for model Mnn1 and experimental data from treatment
Statistic) against the null hypothesis that the residuals are sampled from a normal
M and 1000 nM RHPS4 from ﬁtting model Mn0 (control), model M
n
1 and model M
nn
1
ental data and are shown by error bars.
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ery is depleted, or as the number of cell divisions required before
the drug causes the occurrence of secondary effects leading to
cell death.5. Discussion and conclusions
We have shown that the perception of how the drug RHPS4
affects the cell cycle dynamics is oversimpliﬁed. This was achieved
by choosing a method of analysis which provides more information
on cell cycle dynamics, and more information on the accuracy of
obtained results.
We have combined two different approaches in this work: we
conducted our own experiments and used our measurements for
model ﬁtting. Colorectal cancer cells were plated in media with
different concentrations of RHPS4 for up to 10 days and their
growth properties and cell cycle distribution analysed. The dip in
the total numbers of control cells at day 10 is likely to result from
environment-dependent growth inhibition, as the media has not
been replaced throughout the experiments in order not to inter-
fere with the cells’ natural environment. Also, the number of cells
at day 1 was slightly lower than the value of the initial number of
cells at seeding (day 0), indicating that cells did not replicate
during the ﬁrst day after seeding. This can also be partly due to
not all cells attaching to the bottom of the well after seeding in
media. For simplicity of analysis, we considered day 1 as the start
(t¼0) of the analysis of cell cycle modelling.
As well as cell cycle analysis, we measured the proportion of
nonviable cells by trypan blue dye-exclusion, as DNA degradation is
not an early event of apoptosis and, therefore, should not be taken as
the indicator of cell death (Vermes et al., 2000). Apoptotic cells and
other dead cells split into apoptotic bodies and their DNA degrada-
tion takes place after the onset of cell death. Inaccuracies in
measuring the fractions of pre-G1 cells can arise from one or more
of the following: ﬁrstly, on death, one cell can produce several
fragments each with some DNA content. Secondly, cells can undergo
apoptosis from all phases of the cell cycle, hence debris from a single
S or G2/M cell may not be detected as ‘pre-G1’ at all (Kajstura et al.,
2007) as it has the DNA content of a normal cell (in G0/G1). Since
these reasons include arguments for under- and overestimation of
the actual proportion of late-apoptotic cells, our method of deriving
the pre-G1 fraction can be taken as a good indication for the
frequency of apoptotic cells.
The experimental data were used to ﬁt models of cell cycle
dynamics and the best ﬁt has been identiﬁed. However, model
residuals show some correlations between state variables for
higher concentrations of RHPS4. There was a decisive reduction
in the number of cells treated with 1 mM RHPS4 between days
7 and 10. In particular, the number of harvested cells incubated
for more than 7 days decreased although the respective seeding
densities were the same in these experiments. Dead cells split
into apoptotic bodies and disintegrate in the media making it
hard to detect such cells when counted. Indeed, cell debris was
observed while cells were counted, and a complete disintegration
of apoptotic bodies in the media may have been a reason for
underestimating the number of dead cells as well as the number
of pre-G1 cells towards the end of the observation period.
We report that cells from the HCT116 cell line are affected by
the drug in the S phase after 4 days when the fraction of cells in
this phase drops by 10–20%. The rather temporary effect indicates
that in many treated cells, the effect of the drug is to prevent cells
passing the G1–S check point where a cell commits to the
synthesis phase of cell division. This can be due to cells resolving
certain chromosome replication defects introduced by the drug
until cellular conditions are favourable for the cell division cycle.The decrease in S (and consequently G2/M) phase cells, however,
is only one minor effect of the treatment and we could not fully
explain its causes by our model.
More signiﬁcant is the delayed onset of rapid cell death within
the population of treated cells, occurring largely from the G2/M
phase for 50 nM and from the G0/G1 phase for higher concentra-
tions of RHPS4. The delay decreases with higher drug concentrations
and the mechanisms for the delay remain to be discovered. RHPS4
stabilises G-quadruplexes, which has been found to inhibit telomer-
ase (Gowan et al., 2001), it thus shortens telomeres during replica-
tion. This could cause increased senescence of treated cells. The drug
also causes telomere uncapping leading to apoptosis (Salvati et al.,
2007). We suggest that RHPS4 affects telomeres of colorectal cancer
cells in two ways: ﬁrst, induced telomere shortening may decrease
the fraction of telomeres being in a capped state (Rodriguez-Brenes
and Peskin, 2010), and additional disruption of telomeric proteins
may subsequently cause damage to the uncapped telomeres leading
to activation of damage response pathways in cells traversing S
phase (Rizzo et al., 2009). These ﬁndings could serve as a potential
explanation in particular for the late death of cells treated with
50 nM RHPS4, which we found occurs largely from the G2/M
phase. Secondly, higher concentrations of the drug may lock
the telomeric end in G-quadruplex structures causing severe
replication stress by impairing fork progression in early S phase,
which could explain the earlier onset of cell death for 100 nM and
1 mM of the drug. G-quadruplexes seem not to be compatible with
chromosome replication: they have been observed in vivo
throughout the cell cycle except for the phase of DNA replication
(Lipps and Rhodes, 2009).
In summary, we have shown that the compound RHPS4 has a
concentration-dependent effect on the proliferation of HCT116 cells
and affects cell cycle progression at an early stage of incubation with
the drug. Similar to interpretations of RHPS4-related effects in Rizzo
et al. (2009), who exposed HCT116 cells to the drug for 10 days,
collected data at day 4, 6, 8, 10, and found signiﬁcant growth
inhibition, we suggest that RHPS4 interferes with the replication
fork during DNA synthesis, causing DNA damage and apoptosis.
Cells may initially recover rapidly from the replication stress,
explaining the dip in the S phase proportions at day 4 with a slight,
subsequent increase, but eventually undergo cell death due to the
inability to ﬁx further defects. One explanation is that RHPS4
stabilises G4 structures at the telomeric end creating a barrier for
DNA strand replication; mathematical modelling of telomere repli-
cation processes with interference through G4 formation will be
part of our future investigations.Supplementary material
SRES is a stochastic optimisation algorithm and, therefore,
several runs have to be evaluated to determine the global
minimum, see the ﬁgure in the Supplementary material: optimal
parameter values from the global (SRES, grey dots) and local
optimisation routine (LM, black dots) for 30 runs are plotted with
their optimal function value for a choice of eight parameters, each
run being represented by a dotted line connecting the initial
guess (optimal value from SRES) and the optimal value from the
LM routine. The parameter set that resulted in the overall lowest
cost function value has been chosen and is circled in this ﬁgure.
Results of ﬁtting model Mnn1 to experimental data from treatment
with 50 nM of RHPS4 are shown with the parameter values being
given in units of 1/day. The optimal parameters of the 30 ﬁts do
not differ more than 0.5/day from the parameter value with the
lowest cost function value for each of the different parameters,
only the convergence of kZX and DkZZ is less stable with a
spectrum of about 72.5/day and 72/day, respectively.
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A.1. Suppliers of reagents
We purchased reagents from the following suppliers:
FlowChecks beads: Beckman Coulter Ltd., Buckinghamshire, UK;
Industrial methylated spirits (IMS): Fisher Scientiﬁc Ltd., Leices-
tershire, UK; 3,11-diﬂuoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]
acridinium methosulfate (RHPS4): Pharminox Ltd., Nottingham,
UK; Dimethylsulphoxide (DMSO), foetal bovine serum (FBS),
Ribonuclease A from bovine pancreas (RNAse A), RPMI 1640 liquid
medium (containing 0.3 g/L L-glutamine and 2 g/L sodium bicarbo-
nate), phosphate buffered saline (PBS) tablets, propidium iodide (PI)
(HPLC grade), sodium citrate, Titron X-100, trypsin-EDTA
1 solution, Trypan blue: Sigma-Aldrich Co. Ltd., Dorset, UK.A.2. Drug stock and general cell culture
We used the HCT116 cell line for the biological experiments,
which is one of three strains of human malignant cells isolated
from a male with colonic carcinoma. HCT116 cells grow in a
monolayer and have a relatively short doubling time of 20.5 h
(Brattain et al., 1981). The cell line has been chosen because of its
good sensitivity to RHPS4 and reliable growth properties which
allow analysis of cell viability and cell cycle analysis.
RHPS4 is a water-soluble compound, which facilitates rapid
uptake into cells, and it appeared to be localised in the nuclear
membrane, intranuclear bodies and cytoplasm (Cookson et al.,
2005b). HCT116 colorectal cancer cells were incubated in the
pentacyclic acridinium salt RHPS4 at different concentrations to
analyse its action on the cells for periods of up to 10 days. The
stock of RHPS4 was prepared at a concentration of cst ¼ 10 mM
in DSMO and stored at 4 1C protected from light. The desired
concentrations cas used in assays of Vas ¼ 2 ml each were obtained
by adding a volume of Vst ¼ casVas=ðcstcasÞ from the drug stock.
As Vst is of a smaller order than 10
3 ml for the concentrations of
50 nM, 100 nM and 1 mM used in the assays, the change of
volume in the assays is negligible.
All cell culture techniques were carried out aseptically in a
BioMat2 MDH Class II microbiological safety cabinet with a
laminar ﬂow system. Cells were maintained in Costar tissue ﬂasks
(25 cm2 and 75 cm2) with RPMI 1640 medium, containing addi-
tionally 10% heat-inactivated FBS. FBS was heat inactivated by
heating to 55591C for 1 h, and cooled before addition to RPMI
tissue culture media.
To seed cells at a certain density, all RPMI tissue culture was
aspirated from the ﬂasks and brieﬂy rinsed with sterile PBS. Cells
were detached from the ﬂask with 1 ml trypsin-EDTA per 25 cm2
and resuspended in 6 ml RPMI tissue culture media. The cells
were syringed through a 23 G needle to obtain a near-single
suspension. The total number of cells in the ﬂask was derived by
taking two samples from the ﬂask to count the number of cells
within each sample using a haemocytometer and taking the
average. The cells were seeded at the desired density of cells
by suspending the appropriate amount of cells in RPMI tissue
culture media.HCT116 cells were then grown in 6-well plates in a total
volume of 2 ml of RPMI tissue culture medium per 9.6 cm2 well
and maintained at 37 1C in a 5% CO2, humidiﬁed atmosphere until
preparation for analysis. The initial cell densities vary between
1000 and 200,000 cells per well dependent on the length of time
of incubation, in order to guarantee a conﬂuence level, that is, the
fraction of surface area in the well covered by cells, of less than
80% on the day of analysis (to maximise the proportion of cycling
cells). Cells were incubated for about 5 h or until attached to the
bottom of each well. Treatment of cells with 50 nM, 100 nM or
1 mM of RHPS4 was carried out and cells were reincubated in
unmodiﬁed conditions. Cells were not passaged before the day of
analysis, and they grew at different rates according to drug
concentration and duration for which they were incubated.A.3. Cell cycle analysis
The protocol used for the cell cycle analysis of the HCT116 cell
line was adapted from Riccardi and Nicoletti (2006). To harvest
the cells, all RPMI tissue culture media, possibly containing dead
cells and debris, were collected in FACS tubes and the remaining
cells detached from the ﬂask with 350 ml trypsin-EDTA per well.
The cells were resuspended in the collected tissue culture media
and transferred back into FACS tubes. About 1 ml of PBS solution
was used to wash off the empty wells and to transfer the resulting
solution to the FACS tubes to ensure an as accurate cell count as
possible. To pellet the cells, they were centrifuged at 1200 rpm for
5 min at 4 1C and the supernatant removed. The cell pellet was,
depending on the number of cells, resuspended in 100–500 ml of
PBS and the suspension syringed through a 23 G needle. About
15 ml of the suspension was mixed with 15 ml of 0.4% trypan blue
(staining non-viable cells blue) in microcentrifuge tubes and the
number of viable and dead cells counted in a haemocytometer.
The remaining cells were again centrifuged at 1200 rpm for 5 min
at 4 1C, the supernatant decanted and the pellet resuspended
in 400 ml hypotonic ﬂuorochrome solution, which had been
composed of 50 mg=ml propidium iodide, 0.1% sodium citrate,
0.1% Titron X-100 and 0.1 mg/ml RNAse A in distilled water.
The cells were kept at 4 1C for 24 h in the dark prior to analysis
in which the PI ﬂuorescence of individual nuclei was measured
using a Coulter Epics XL-MCLTM ﬂow cytometer operated using
Expo32TM software. Before using the Coulter Epics XL-MCLTM ﬂow
cytometer, a quality control check was carried out according to
the manufacturer’s instructions to monitor instrument alignment
using FlowCheck s beads. When the quality control check was
satisfactory, the cells were analysed. List mode data for ﬂuores-
cence emission in the FL3 channel (representing PI ﬂuorescence)
of particles were collected. The ﬂow rate was set to low and a
minimum of 20,000 cells was analysed. We used a dot plot of FL3
against AUX (channel for peak ﬂuorescence signal) of all detected
events to distinguish single cells from unwanted doublets as
described in Nunez (2001).
The proportion of cells in each phase of the cell cycle (pre-G1,
G1/G0, S and G2/M) was estimated by setting gates manually on
the DNA content histograms obtained from FL3 ﬂuorescence of
single cells and using the software package WinMDI (freeware
designed by J. Trotter, allowing the removal of doublets via gating
of list mode data).
We are interested in the response of cells to four different
levels of the drug and accordingly investigated the cell cycle
distribution and cell viability in each assay throughout a period of
10 days. Every experiment was set up with six replicates to assess
the variability associated with the cell growth cycle: the cells
were incubated and treated with RHPS4, and cell counting was
conducted.
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plates, where the seeding densities were chosen carefully as too
dense cell-to-cell contacts can inhibit cell growth, but on the other
hand, sufﬁcient cell numbers are needed both for meaningful cell
cycle analysis and to allow for comparable cell environments across
experiments. The seeding densities correspond to estimates of the
population growth in each experiment. Higher initial seeding
densities were used for treated cells to compensate for reduced
population doublings. Contrary to common procedures, we did not
split cells during culture, but adjusted seeding densities for each
assay in order to minimise disruption of the natural cell growth.
The total number of doublings (TND), for each concentration of
the drug, and for each day i of analysis, was computed for each
experiment using the formula
TNDiðtÞ ¼
ln NiðtÞln Nið0Þ
ln 2
, ðA:1Þ
where TNDiðtÞ and Ni(t) are, at time point t, the total number of
doublings and the total number of cells, respectively, from the
experiment used to analyse cells at day i. We now assume that
the total number of doublings is independent of the initial
seeding density and write TNDi ¼ TND for all i.
Now we consider an experiment, where all initial seeding
densities are identical, and normalise our data by setting Nið0Þ ¼
103 for all i. The normalised data set can be derived from the
original data by
NðtÞ ¼ 103  2TNDðtÞ ¼ 103 NiðtÞ
Nið0Þ
, ðA:2Þ
where N(t) is the total number of cells that have grown from 103
cells in t days. The number of cells in each phase of the cell cycle,
including the number of viable and dead cells, can then be obtained
by multiplying the respective proportions with N(t).Appendix B. Doubling times/residence times
A quantity of biological interest is the doubling time of cells,
which is the period of time required for a population of cells
to double its cell numbers. It is a characteristic unit for the
description of cell growth providing a more intuitive notion of the
long-term impact of growth.
For constant transition rates k, we can approximate the doubling
time from the model dynamics by considering the subsystem of
Eqs. (1)–(3) in Section 2.1, which represents the cell cycle dynamics
of viable cells as illustrated in Fig. 1. The eigenvalues xj of the
respective coefﬁcient matrix
M¼
kXYkXX 0 2kZX
kXY kYZkYY 0
0 kYZ kZXkZZ
0
B@
1
CA, ðB:1ÞTable C.1
Upper triangular part of the correlation matrix dCorrðp^Þ computed as in (C.1) for mode
p^k kXY kYZ kZX kZZ0 Dk
kXY 1 0.3705 0.7089 0.5611 0
kYZ 1 0.1513 0.1607 0
kZX 1 0.9617 0
k
ZZ0
1 0
Dk
XX
1
Dk
YY
Dk
ZZ
t0
kZAdetermine the behaviour of X, Y and Z, and if the largest eigenvalue,
say xs, is positive, we expect exponential growth behaviour for the
total number of cycling cells. The doubling time can in this case be
approximated by
Td ¼
ln 2
xs
, ðB:2Þ
through solving 2ðXðtÞþYðtÞþZðtÞÞ ¼ XðtþTdÞþYðtþTdÞþZðtþTdÞ
for large values of t. For exponential decay ðxso0Þ, the absolute
value of Td gives the half-life of the cell population.
The residence time of cells in a particular cell-cycle phase is
the average amount of time a cell spends in that phase. For a
compartment, say X, with losses from the X compartment only of
rate kXY, it is well-known that the probabilistic waiting time, tX , to
the next transition from X to Y is exponentially distributed with
mean 1=kXY , that is tX  expð1=kXY Þ. We introduce the probabil-
istically-motivated notion of the residence time, being the
expected value of the waiting time, into our deterministic model,
and set
TX ¼
1
kXY
, TY ¼
1
kYZ
, TZ ¼
1
kZX
, ðB:3Þ
for the residence times of cells in the X, Y and Z compartments.
For non-negligible losses (rate kn0) from any of the three com-
partments to cell death, we have to correct our formulas for the
residence time, and set TX ¼ 1=ðkXYþkXX0Þ, TX ¼ 1=ðkYZþkYY0Þ,
TZ ¼ 1=ðkZXþkZZ0Þ.Appendix C. Correlation coefﬁcients for rate parameters
The correlation matrix
dCorrðp^Þ ¼ R^ ijﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
R^ iiR^jj
q
0
B@
1
CA, ðC:1Þ
where R^ ¼ R^ðp^Þ is as deﬁned in Section 3.2, provides us with
information on the degree of linear dependence between para-
meters. The entries of dCorrðp^Þ, say rijðp^Þ, i,j¼ 1, . . . ,L, have the
property 9rijðp^Þ9r1, where we have perfect positive (negative)
linear relationship between the parameter estimates p^i and p^j for
rijðp^Þ ¼ 1 ðrijðp^Þ ¼1Þ and no correlation for rijðp^Þ ¼ 0. Table C.1
presents the correlation coefﬁcients for the estimated parameters
in model Cnn.Appendix D. Supplementary material
Supplementary data associated with this article can be found
in the online version, at doi:10.1016/j.jtbi.2011.10.038l Mnn1 and data from treatment with 50 nM RHPS4.
XX
Dk
YY
Dk
ZZ
t0 kZA
.6719 0.3118 0.7014 0.0160 0.1211
.3471 0.7008 0.0754 0.2058 0.0167
.4064 0.0605 0.6632 0.1068 0.4296
.2750 0.0385 0.5167 0.2015 0.5210
0.3917 0.7752 0.3833 0.0714
1 0.0711 0.0366 0.0365
1 0.0261 0.1145
1 0.0351
1
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